Caris expands its extensive network of leading cancer institutions committed to improving patient outcomes through innovations in precision medicine by welcoming Mass General Cancer Center. “We are thrilled to welcome Mass General Cancer Center, one of the world’s most respected centers, to the Caris Precision Oncology Alliance,” said George Sledge, Jr., MD, EVP and Chief Medical Officer of Caris. “We’re eager to work with their researchers and investigators on our shared mission of improving outcomes of all patients affected by cancer through precision oncology research.” Learn more: https://lnkd.in/ggni-zgg
Caris Life Sciences’ Post
More Relevant Posts
-
June is Men's Health Month, and at Caris Life Sciences, we're committed to helping men receive personalized cancer care. Discover how molecular profiling can be beneficial: https://lnkd.in/gZ_sUcny #MensHealthMonth
-
-
June is National Cancer Survivor Month, and we are honoring the incredible strength and resilience of cancer patients, caregivers and families. Join us in celebrating these brave individuals and learn how we can continue to support those with cancer. Learn more: https://lnkd.in/gttPBvN3 #NationalCancerSurvivorMonth
-
Unleash the power of liquid biopsy with Caris Assure. This groundbreaking multi-cancer assay offers deep molecular insights from a simple blood sample. Discover how this powerful liquid biopsy assay can transform patient care. Learn more: https://ow.ly/Vxvn50QSvoc
Less Invasive, More Intelligent Than Ever
-
That’s a wrap for ASCO 2024! We want to express our sincere gratitude to the numerous visitors who graced the Caris Life Sciences booth with their presence. It was a pleasure engaging with each of you to explore avenues for advancing precision medicine. Caris remains steadfast in its dedication to improving as many lives as possible. Discover more about our mission: https://lnkd.in/gX69hvc5 #ASCO24 #precisionmedicine
-
Join Caris Life Sciences scientific and medical leaders as they discuss Caris Assure for Therapy Selection. Caris Assure is a blood liquid biopsy that sequences plasma and buffy coat to report tumor-derived, incidental germline, and incidental CH variants. Presenters will review cases that highlight the strengths of liquid biopsy in a clinical workflow. Discover the power of Caris Assure, the next evolution of blood-based profiling, and register today: https://lnkd.in/geabwTc4 #precisionmedicine
-
-
We're thrilled to share that Caris Life Sciences is ranked among the top ten biopharma deals of 2024! Our collaboration with Merck KGaA, Darmstadt, Germany, is featured in a recent article by Nature, highlighting the agreement's impact. This partnership is helping to accelerate the discovery and development of Merck KGaA, Darmstadt, Germany's first-in-class antibody-drug conjugates (ADCs) for cancer patients. Learn more: https://lnkd.in/g9qPNfSG
-
-
Caris Life Sciences ASCO 2024 Poster Presentations Wrap-Up ▶ Slide 1: 🏅 Merit Award Winner The molecular landscape of pembrolizumab and lenvatinib treatment in endometrial cancer ▪ Presenter: Erica Carballo ▶ Slide 2: Genomic and tumor microenvironment dynamics of brain metastases in breast cancer ▪ Presenter: Dharmini Manogna ▶ Slide 3: Young adults (YA) with non-small cell lung cancer (NSCLC): Snapshot of the oncogenic drivers and immune landscapes ▪ Presenters: Aaron Pruitt, MD Andrew Elliott, Ph.D. ▶ Slide 4: Metabolic profile and therapeutic vulnerabilities of multi-omic characterization of KRAS/STK11/KEAP1 co-mutant non–small cell lung cancer (NSCLC) ▪ Presenters: Andrew Elliott, Ph.D. Triparna Sen, PhD, MS, BS Balazs Halmos, MD ▶ Slide 5: Characterizing FOLR1 expression in low-grade serous ovarian carcinoma ▪ Presenter: Tullia Rushton ▶ Slide 6: Multidimensional analysis of B7 homolog 3 (B7-H3) RNA expression in small-cell lung cancer (SCLC) molecular subtype ▪ Presenter: Carl Gay
